by Vora Corporate Finance | Jul 4, 2024 | Insights, Private Equity & IPO
Transaction: Quadria Capital, one of Asia’s largest healthcare-focused private equity firm invested INR 850 Crores in a series F funding round of NephroPlus, valuing the company at more than Rs. 2000 Crores. Through this transaction, Quadria acquires significant...
by Vora Corporate Finance | Jan 18, 2021 | Insights, Private Equity & IPO
Hyderabad based Gland Pharma Ltd. is an injectable-focused company with a footprint in 60 countries. Company mainly operates in complex injectable under B2B model. The issue price of the stock was kept Rs. 1490 to Rs. 1500 per share at P/E of around 30. IPO was...
by Vora Corporate Finance | Jan 16, 2021 | Insights, Private Equity & IPO
Biocon Ltd., a bio-pharmaceutical company, announced that the Board of its subsidiary Biocon Biologics Ltd (Biocon Biologics) has approved a Rs.1,125 Crore (approx. USD 150 million) fund raise from Goldman Sachs. As per the proposed terms, Goldman Sachs will be issued...
by Vora Corporate Finance | Jan 16, 2021 | Insights, Merger & Acquisitions
Manipal Health Enterprises Pvt. Ltd. announced that it will buy the Indian assets of Columbia Asia Hospital Group for around Rs.1800 Crore. Manipal will also absorb the debt of Columbia Asia of Rs.300 Crore. Manipal Hospitals is a multi-specialty healthcare providers...
